Anxiety Medicine Names: Drug Classes Used in India
Anxiety medicine names by drug class used in India: SSRIs, SNRIs, benzodiazepines and buspirone, their evidence base and Schedule H1 status.
This piece covers the evidence base separating these anxiety medicine names by tier, why benzodiazepines carry a different regulatory status in India, and what that means for hospital pharmacy stocking and dispensing practice.
Why are SSRIs and SNRIs first-line for anxiety disorders?
SSRIs and SNRIs, alongside pregabalin, are positioned as first-line pharmacotherapy for generalized anxiety disorder in evidence-based treatment reviews, chosen specifically for their comparatively favourable long-term adverse-event profile. For panic disorder specifically, fluoxetine, sertraline and paroxetine carry regulatory approval in major markets, reflecting the strongest evidence base within the SSRI class for that particular anxiety subtype.
This first-line positioning is about the balance of chronic-use safety against benzodiazepines' dependence risk, not a claim that SSRIs work faster. SSRIs and SNRIs typically take several weeks to reach full therapeutic effect, a genuine clinical trade-off against benzodiazepines' rapid onset that shapes how the two classes get combined in practice.
Where do benzodiazepines fit among anxiety medicine names?
Benzodiazepines are positioned as second-line treatment in major prescribing guidelines, used after non-response to SSRIs, SNRIs, pregabalin or buspirone, according to the British Association for Psychopharmacology's guidance. Their advantage is rapid onset of therapeutic effect, which is why they remain widely used for acute anxiety flares despite not being first-line for chronic maintenance therapy.
That second-line positioning exists because of a well-documented trade-off: benzodiazepines carry a relatively high incidence of dependence and genuine difficulty with discontinuation, a concern guideline bodies have flagged directly rather than treating as a minor caveat. Alprazolam specifically works by enhancing GABA-A receptor activity, the brain's principal inhibitory signalling pathway, which is the same mechanism responsible for both its calming effect and its dependence liability.
What withdrawal and monitoring risks come with benzodiazepine-class anxiety medicines?
Physical dependence on alprazolam develops with chronic use, particularly at higher doses, and rapid dose reduction or abrupt discontinuation can precipitate acute withdrawal severe enough to be life-threatening, according to NIH clinical reference material. Gradual tapering, rather than stopping, is the standard approach once a patient has been on the drug long enough to develop dependence.
Ongoing monitoring for a patient on long-term benzodiazepine therapy includes respiratory and cardiovascular status, signs of excessive sedation or orthostatic hypotension, and periodic liver function and blood count checks, alongside screening for emerging depression or suicidal ideation, since anxiety and mood disorders frequently coexist.
How is alprazolam regulated in India compared to SSRIs?
Alprazolam sits in Schedule H1 of the Drugs and Cosmetics Rules 1945, the same stricter dispensing tier that governs other habit-forming drugs: every dispensation requires the pharmacy to retain the original prescription and log it in a dedicated register available for regulatory inspection. SSRIs and SNRIs, by contrast, are Schedule H prescription-only medicines without that additional register requirement.
| Drug class | Example agents | Regulatory tier in India | Typical clinical role |
|---|---|---|---|
| SSRI | Fluoxetine, sertraline, paroxetine | Schedule H | First-line, chronic maintenance |
| SNRI | Venlafaxine, duloxetine | Schedule H | First-line alternative to SSRIs |
| Non-benzodiazepine anxiolytic | Buspirone | Schedule H | Alternative when benzodiazepine dependence risk is a concern |
| Benzodiazepine | Alprazolam, clonazepam | Schedule H1 | Second-line, acute/short-term use |
Why does this regulatory distinction matter to a hospital pharmacy?
A hospital pharmacy dispensing Schedule H1 benzodiazepines needs a register that a Schedule H-only formulary doesn't require, and it needs that register current, or every dispensation carries genuine inspection risk. A pharmacy that can't dispense a prescribed benzodiazepine in-house because the register has lapsed sends that prescription, and the visibility into how often a dependence-prone drug is being refilled, to an outside chemist.
Our managed hospital pharmacy services guide covers how an in-house pharmacy keeps Schedule H1 register compliance current for exactly this drug category. Our prescription leakage guide covers what a hospital loses in continuity of care and revenue when that prescription walks out the door instead. Our hospital pharmacy management guide covers the broader register and compliance discipline a Schedule H1-heavy formulary demands.
Sources
- 1Pharmacotherapy for Generalized Anxiety Disorder in Adults and Pediatric Patients: An Evidence-Based Treatment Review — National Institutes of Health, National Library of Medicine
- 2Representation of Benzodiazepines in Treatment Guidelines: The Paradox of Undesirable Objectivity — Psychotherapy and Psychosomatics, Karger
- 3Alprazolam — StatPearls — National Institutes of Health, National Library of Medicine
- 4Drugs and Cosmetics Rules 1945 — Central Drugs Standard Control Organisation
- 5National List of Essential Medicines 2022 — Central Drugs Standard Control Organisation
This article is for informational purposes and is not a substitute for professional medical advice. It describes drug classes and their evidence base for clinical reference; it does not recommend a specific medicine for any individual patient. Consult a qualified psychiatrist or physician for diagnosis and treatment planning.
FAQ
Frequently asked questions
SSRIs and SNRIs, along with pregabalin, are positioned as first-line pharmacotherapy in evidence-based treatment guidelines, chosen for their more favourable long-term safety profile compared to benzodiazepines.
Alprazolam carries a documented risk of physical dependence with chronic use, and guidelines position benzodiazepines as second-line treatment specifically because of this risk, reserved for acute flares or non-response to first-line agents rather than routine long-term maintenance.
Schedule H1 applies to habit-forming drugs requiring stricter dispensing controls, including a dedicated pharmacy register and retained original prescription; alprazolam's documented dependence potential places it in this tier, while SSRIs and SNRIs do not carry the same dependence profile.
No. Abrupt discontinuation after chronic use can precipitate acute withdrawal that may be severe or life-threatening; gradual, supervised tapering is the standard clinical approach.
Buspirone is a non-benzodiazepine anxiolytic used as an alternative anxiety treatment without the same dependence and withdrawal profile as benzodiazepines, though it typically takes longer to reach full therapeutic effect.
Dr. Priya MenonMBBS, MD (General Medicine)
Consultant Physician (Internal Medicine)
Dr. Priya Menon is a consultant physician in internal medicine, writing on drug classes, side-effect profiles, and evidence-based clinical use for hospital and prescriber audiences.